The TCSP biomarker better predicted DCB (AUC = 0.78) compared to both the indicated companion diagnostic, PD-L1 IHC (AUC = 0.73), and also Tumor Mutational Burden (AUC = 0.71) (Fig. 4E). This evidence concerns the gene CD274 and neoplasm.